Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
TPG Capital Asia has agreed to acquire Poonawalla Housing Finance for a pre-money equity valuation of INR 39bn (USD 473m) and inject an additional INR 10bn to support growth.
Temasek Holdings, Sequoia Capital China, and IDG Capital have led a CNY500m (USD 72m) Series B investment in Chinese solar cell manufacturer GCL Photoelectric Materials.
As China’s technology space has shifted toward more advanced domains of R&D, bubbles have formed and geopolitics have complicated investment. There is scope for some turnaround on these points
Southeast Asia VC is in fair position to hobble through a global downturn and cooling appetite for all things tech despite controversial politics in the region’s largest market and a dicey IPO outlook
Indiemicro, a Chinese chip designer targeting the automotive industry has raised a CNY300m (USD 43m) round featuring semiconductor-focused Sunic Capital.
Fundraising favours the few; deployment becomes progressively slower as investors agonise about valuations, macro prospects, and financing costs; sponsor-to-sponsor deals prop up exits
New Zealand’s Partly, a company that uses big data to source replacement parts for the global automotive industry, has raised a NZD 37m (USD 21m) Series A round led by UK-based Octopus Ventures.
Australia-based specialist B2B technology investor Potentia Capital appears to be continuing its pursuit of two listed companies – Nitro Software and Tyro Payments – despite several rejections.
Eswin Material, the integrated circuit manufacturing unit of Eswin Technology Group, has raised CNY 4bn（USD 576m）in Series C funding led by the New Materials Fund of China National Building Material.
Seoul-based education technology start-up Mathpresso has closed its Series C round on USD 70m following an investment of undisclosed size last year from Google.
Korea-headquartered cloud services company Bespin Global has raised a USD 100m Series D round led by a unit of Emirates Telecoms Group.
Dubai-based Winter Capital has led a USD 22.5m Series A round for Indian education technology platform Uolo with support from local investor Blume Ventures.
BPEA EQT – formerly Baring Private Equity Asia – has pulled out of its planned acquisition of a majority stake in Korea-based industrial films producer PI Advanced Materials from Glenwood Private Equity.
Hillhouse Capital has agreed to buy George Clinical, an Australia-based clinical research organisation (CRO) with a global footprint, for an undisclosed sum.
SuZhou LavaMed, a China-based medical devices manufacturer, has raised USD 40m in angel and Series A funding from Zhejiang Silk Road Fund, Junshang Capital, and Lilly Asia Ventures (LAV).
Goldman Sachs Asset Management (GSAM) has made a structured investment in Goodpack, a Singapore-based container manufacturer controlled by KKR, as part of a broader refinancing transaction.
Japan’s Sparx Group has led an investment in Singapore-based internet-of-things (IoT) developer UnaBiz. It completes a USD 50m Series B round that started in October last year.
Hong Kong’s E15 VC has hit a first close of USD 60.75m on its third global deep tech fund with an anchor investment from existing cornerstone LP Sun Hung Kai & Co (SHK).
Square Peg Capital and Wellington Management have led a AUD 750m (USD 501m) investment in Australian e-commerce marketing technology provider Rokt at a valuation of USD 2.4bn.
EQuest Education, a Vietnam-based operator of bilingual schools backed by KKR, has acquired a controlling interest in industry peer Khoi Nguyen Education Group (KNE).
Thoma Bravo, a specialist investor in software companies, has closed its latest set of buyout funds with more than USD 32.4bn in commitments. This compares to USD 22.8bn in the previous vintage.
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.